MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

GenMark Diagnostics Company Profile (NASDAQ:GNMK)

Consensus Ratings for GenMark Diagnostics (NASDAQ:GNMK) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.00 (52.91% upside)

Analysts' Ratings History for GenMark Diagnostics (NASDAQ:GNMK)
Show:
DateFirmActionRatingPrice TargetActions
8/10/2015Canaccord GenuityReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015BTIG ResearchReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Canaccord GenuityReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015BTIG ResearchReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Canaccord GenuityLower Price TargetBuy$16.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2015BTIG ResearchReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2015Canaccord GenuityLower Price TargetIn-Line -> Buy$17.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015Needham & Company LLCSet Price TargetBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Needham & Company LLCSet Price TargetBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015BTIG ResearchReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Canaccord GenuitySet Price TargetBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2014BTIG ResearchUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2014Raymond JamesReiterated RatingOutperform$11.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014Raymond JamesReiterated RatingOutperform$14.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014JPMorgan Chase & Co.Reiterated RatingOverweight$17.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014Cowen and CompanyReiterated RatingOutperform$16.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/24/2014Canaccord GenuityBoost Price Target$14.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2013Needham & Company LLCInitiated CoverageBuy -> Buy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2013Raymond JamesLower Price TargetOutperform$15.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/14/2013Piper JaffrayReiterated RatingOverweight$9.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2013Raymond JamesBoost Price Target$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 9/3/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha